Wednesday, February 5, 2025
2/5/2025
PROJECT SUMMARY The aim of this proposal is to discover the cellular and molecular pathways regulated by IL-13 that promote B cell production of high affinity IgE to allergens. Despite the importance of IgE in allergic responses, the signals that instruct B cells to produce high affinity, sialylated and long-lived IgE are not well understood. Recently we discovered in mice and humans a rare subset of T follicular helper (Tfh) cells, known as Tfh13 cells, that produce IL-13 and are required for high affinity IgE production. Ablation of of IL-13 specifically from Tfh13 cells causes a loss of high affinity IgE and prevents anaphylaxis. Additionally, we have demonstrated that the receptor for IL- 13, IL-13 receptor alpha 1 (IL-13Rα1), is highly expressed on IgG1 GC B cells, IgE GC B cells, and IgE plasma cells as compared to naïve B cells. These findings suggest that Tfh13-derived IL-13 acts directly on B cells to promote high affinity IgE responses. However, where in the lymph node Tfh13 cells interact with B cells and how Tfh13-produced IL-13 promotes high affinity IgE production are unknown. Our hypothesis is that IL-13 acts on IgE+ B cells to promote their survival. In Aim 1, we will identify the stage of mouse and human IgE+ B cell differentiation and/or functions that are regulated by IL-13. We will use specialized in vitro culture systems to generate both mouse and human germinal center-like B cells to test whether IL-13 promotes IgE switching, IgE+ plasma cell differentiation, or IgE+ plasma cell survival. We will also use mass spectrometry to investigate whether Tfh13 cells and/or IL-13 play a role in the regulation of IgE glycosylation in vitro and in vivo. Additionally, we will determine whether the expression of IL13Rα1 differs on various B cell subsets in allergic versus healthy donors and will test how this impacts their response to IL-13. In Aim 2, we will define the role of IL-13Rα1 on mouse IgE+ B cells in vivo. To achieve this, we will use high-resolution immunofluorescence imaging and spatial transcriptomics/proteomics to characterize the sub-anatomic regions in the lymph node where IL-13-expressing Tfh13 cells and B cells interact. Additionally, using a novel conditional Il13ra1 knockout mouse we generated we will determine which stages of the IgE+ B cell response are disrupted by the loss of IL-13 stimulation in vivo. Lastly, we will investigate whether B cell intrinsic IL-13Rα1 is necessary for the production of sialylated and high affinity IgE to allergens and downstream anaphylaxis in vivo. In Aim 3, we will identify the IL13Rα1-specific signaling pathways that promote IgE production by mouse and human B cells. To accomplish this, we will use a combination of phospho flow, ChIP-Seq, and RNA-Seq to characterize STAT6-dependent and -independent signaling pathways in human and mouse B cells downstream of IL-4 versus IL-13 stimulation. Subsequently, we will use knockout cells and inhibitors to alter the balance of type I and type II receptor signaling downstream of IL-4 and IL-13. Impact: If successful, this work will define the immunologic rules that govern IgE production by high affinity B cells and will identify targetable genetic and environmental factors that dictate pathologic IgE antibody responses in those with allergy.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).